Linden Thomas Advisory Services LLC Acquires 541 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Linden Thomas Advisory Services LLC raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.9% in the 4th quarter, HoldingsChannel reports. The firm owned 6,000 shares of the pharmaceutical company’s stock after purchasing an additional 541 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Vertex Pharmaceuticals were worth $2,441,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Parkside Financial Bank & Trust raised its position in Vertex Pharmaceuticals by 25.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 807 shares of the pharmaceutical company’s stock valued at $328,000 after purchasing an additional 162 shares during the last quarter. Illinois Municipal Retirement Fund raised its position in Vertex Pharmaceuticals by 3.6% in the 4th quarter. Illinois Municipal Retirement Fund now owns 86,720 shares of the pharmaceutical company’s stock valued at $35,286,000 after purchasing an additional 3,033 shares during the last quarter. California Public Employees Retirement System raised its position in Vertex Pharmaceuticals by 0.4% in the 4th quarter. California Public Employees Retirement System now owns 1,515,816 shares of the pharmaceutical company’s stock valued at $616,770,000 after purchasing an additional 5,855 shares during the last quarter. RWA Wealth Partners LLC raised its position in Vertex Pharmaceuticals by 330.7% in the 4th quarter. RWA Wealth Partners LLC now owns 3,618 shares of the pharmaceutical company’s stock valued at $1,472,000 after purchasing an additional 2,778 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Vertex Pharmaceuticals by 3.9% in the 4th quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock valued at $1,605,146,000 after purchasing an additional 147,248 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,381 shares of company stock valued at $5,203,249. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.5 %

NASDAQ:VRTX traded up $6.12 on Tuesday, reaching $406.04. The company’s stock had a trading volume of 512,871 shares, compared to its average volume of 1,238,390. Vertex Pharmaceuticals Incorporated has a 1-year low of $316.43 and a 1-year high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The firm has a market cap of $104.95 billion, a PE ratio of 29.18, a PEG ratio of 1.86 and a beta of 0.35. The business’s 50-day moving average price is $413.23 and its two-hundred day moving average price is $398.05.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The firm had revenue of $2.52 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period in the previous year, the firm earned $3.33 earnings per share. Equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on VRTX. Guggenheim boosted their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Royal Bank of Canada boosted their target price on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Canaccord Genuity Group restated a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, April 12th. Cantor Fitzgerald restated an “overweight” rating and set a $440.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Finally, William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $429.45.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.